Clinical Trials

A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients with Hematologic Malignancies


Study ID
Jazz Pharmaceuticals-CPX351-102

NCT Number
NCT03555955 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0353

Principle Investigator
Dr. Jamie Koprivnikar

Phase
I

Sponsor
Jazz Pharmaceuticals


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now